Information Provided By: 
Fly News Breaks for June 5, 2018
TXMD
Jun 5, 2018 | 07:26 EDT
Cantor Fitzgerald analyst William Tanner believes Imvexxy will become an important new treatment for vulvar vaginal atrophy. Given the high degree of dissatisfaction with current genitourinary syndrome of menopause treatments, Imvexxy "could be poised to surprise on the pace of market uptake," Tanner tells investors in a research note. He reiterates an Overweight rating on TherapeuticsMD shares with a $26 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
